TheEdgeResearch
Home / Stocks / QTRX

Quanterix Corporation (QTRX)

NASDAQ Healthcare Medical - Devices
$1.96 ▼ -3.45%
Market Cap
$93.1M
Sector
Healthcare
Industry
Medical - Devices
Beta
1.04
52-Wk Range
1.765-8.77
CEO
Everett V. Cunningham
Country
US
Currency
USD

Quanterix Corporation operates in the Medical - Devices industry of the Healthcare sector, headquartered in Billerica, MA, US. The stock last traded at $1.96, down 3.45% on the session, giving a market capitalisation of $93.1M. On trailing twelve-month figures it carries a trailing P/E of -0.83, a net margin of -75.0%. Its beta of 1.04 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.83
Price / Sales
0.63
Price / Book
0.42
EV / EBITDA
-0.98
Gross margin
41.6%
Operating margin
-79.2%
Net margin
-75.0%
Return on equity
—
Debt / equity
0.14
Current ratio
3.09
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
450
IPO date
2017-12-07
Headquarters
Billerica, MA, US
About Quanterix Corporation

Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.

Comparable companies

Quanterix Corporation is most often compared with the following Healthcare names:

CVRXIMRXINGNMASSNNOXOMSENSSGHTSNWVVMD
More research on QTRX
QTRX technical analysis QTRX TheEdge Score Compare against peers
Open full interactive analysis & DCF →